Literature DB >> 22945589

Experimental arthritis: JAK inhibition with tofacitinib curbs RANKL-induced joint damage.

Sarah Onuora.   

Abstract

Entities:  

Year:  2012        PMID: 22945589     DOI: 10.1038/nrrheum.2012.147

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.

Authors:  Timothy P LaBranche; Michael I Jesson; Zaher A Radi; Chad E Storer; Julia A Guzova; Sheri L Bonar; Janice M Thompson; Fernando A Happa; Zachary S Stewart; Yutian Zhan; Chris S Bollinger; Prashant N Bansal; Jeremy W Wellen; Dean P Wilkie; Steven A Bailey; Peter T Symanowicz; Martin Hegen; Richard D Head; Nandini Kishore; Gabriel Mbalaviele; Debra M Meyer
Journal:  Arthritis Rheum       Date:  2012-11
  1 in total
  1 in total

Review 1.  The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.

Authors:  Yasuko Furumoto; Massimo Gadina
Journal:  BioDrugs       Date:  2013-10       Impact factor: 5.807

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.